Form 4 for CRSP CRISPR Therapeutics AG
Accepted 2021-08-10 00:00:00 ET · period of report 2021-08-06 · accession 0001209191-21-050719 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2021-08-10 | 2021-08-06 | CRSP | TOMSICEK MICHAEL JOHN | CFO | M - OptEx | $17.75 | +25.0K | 26.9K | +1,322% | +$443.8K |
| DM | 2021-08-10 | 2021-08-06 | CRSP | TOMSICEK MICHAEL JOHN | CFO | S - Sale+OE | $138.52 | -25.0K | 1,891 | -93% | -$3.46M |
| D | 2021-08-10 | 2021-03-11 | CRSP | TOMSICEK MICHAEL JOHN | CFO | M - OptEx | $0.00 | -25.0K | 131.0K | -16% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2021-08-06 | M | A | 25,000 | $17.75 | 26,891 | D | — | — | |
| 2 | Common | Common Shares | 2021-08-06 | S | D | 19,011 | $138.22 | 7,880 | D | — | — | (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $138.00 to $138.97, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| 3 | Common | Common Shares | 2021-08-06 | S | D | 5,989 | $139.46 | 1,891 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.06 to $139.69, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. |
| 4 | Derivative | Stock Option (Right to Buy) | 2021-03-11 | M | D | 25,000 | $0.00 | 131,000 | D | $17.75 · — to 2027-11-21 | 25,000 Common Shares | (F4) This option was granted on November 13, 2017, 25% of the shares vested on November 13, 2018 and the remaining shares vest in 36 equal monthly installments on the first day of each succeeding calendar month. |